Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Market Cap	32.14M +12.1%
Revenue (ttm)	n/a
Net Income	-6.82M
EPS	-0.14
Shares Out	51.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	16,311
Open	0.6200
Previous Close	0.6250
Day's Range	0.6200 - 0.6200
52-Week Range	0.5100 - 0.8800
Beta	0.59
RSI	51.89
Earnings Date	Apr 24, 2026

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Patrice Rioux
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TTI